News | July 29, 2021
Astec Lifesciences 1FY22 consolidated PAT at Rs. 12.98 Cr
The company posted net profit of Rs.16.18 crores for the period ended June 30, 2020.
The company posted net profit of Rs.16.18 crores for the period ended June 30, 2020.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
Essential medicines were made available to more than 150 countries around the world during the pandemic
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Subscribe To Our Newsletter & Stay Updated
